Poseida Therapeutics Inc. (PSTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
PSTX Stock Price Chart Interactive Chart >
PSTX Price/Volume Stats
| Current price | $9.47 | 52-week high | $17.62 |
| Prev. close | $9.34 | 52-week low | $7.63 |
| Day low | $9.17 | Volume | 273,000 |
| Day high | $9.64 | Avg. volume | 313,936 |
| 50-day MA | $8.84 | Dividend yield | N/A |
| 200-day MA | $9.75 | Market Cap | 588.61M |
Poseida Therapeutics Inc. (PSTX) Company Bio
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in 2014 and is headquartered in San Diego, CA.
Latest PSTX News From Around the Web
Below are the latest news stories about Poseida Therapeutics Inc that investors may wish to consider to help them evaluate PSTX as an investment opportunity.
Poseida Therapeutics Announces Virtual 2021 Annual Meeting of StockholdersPoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that its Annual Meeting of Stockholders (the "Annual Meeting") will be held virtually via live webcast on Wednesday, June 16, 2021 at 1:00pm PT. Stockholders of record at the close of business on April 20, 2021, are entitled to vote in the Annual Meeting. |
Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the first quarter ended March 31, 2021. |
Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs at the American Society of Gene and Cell Therapy 2021 Virtual Annual MeetingPoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today will give multiple oral and poster presentations at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting being held May 11-14, 2021. |
Poseida Therapeutics to Present at Upcoming Virtual Investor ConferencesPoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company will participate in the following upcoming virtual investor conferences: |
Why Poseida Therapeutics Stock Is Popping TodayWhat happened Shares of Poseida Therapeutics (NASDAQ:PSTX) were jumping 21.2% higher as of 12:08 p.m. EST on Wednesday. The big gain came with the company providing a pipeline update at its virtual R&D Day today. |
PSTX Price Returns
| 1-mo | 12.74% |
| 3-mo | -8.77% |
| 6-mo | -9.81% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -13.67% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...